ECM
RVMD icon

Everence Capital Management’s Revolution Medicines RVMD Stock Holding History

Everence Capital Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
6,152
+750
+14% +$110K 0.06% 232
2026
Q1 		$525K Buy
5,402
+772
+17% +$78K 0.03% 364
2025
Q4 		$369K Hold
4,630
– – 0.02% 508
2025
Q3 		$216K Buy
+4,630
New +$181K 0.01% 743
2025
Q1 		– Sell
-4,630
Closed -$203K – 833
2024
Q4 		$203K Buy
+4,630
New +$234K 0.01% 779

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Everence Capital Management's RVMD Position: Q2 2026 in Review

Everence Capital Management increased its Revolution Medicines (RVMD) stake by 14% in Q2 2026, buying an estimated $110K and bringing the position to 6,152 shares worth $1.15M. The position accounts for 0.06% of the portfolio, ranked #232.

Everence Capital Management first reported a position in RVMD in Q4 2024 and has held it in 5 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Everence Capital Management held 6,152 shares of Revolution Medicines worth $1.15M as of Q2 2026.
  • Everence Capital Management bought 750 Revolution Medicines shares in Q2 2026, an estimated $110K.
  • Revolution Medicines made up 0.06% of Everence Capital Management's portfolio in Q2 2026, its #232 holding.
  • Everence Capital Management first reported a position in Revolution Medicines in Q4 2024 and has held it in 5 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.